Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

336
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
336
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

346
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
346
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

337
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
337
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

359
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
359
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

321
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
321
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

147
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
147

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improving Appropriateness and Timeliness of Antibiotic Delivery in Pediatric Intestinal Failure.

Pediatric emergency care·2026
Same author

Unveiling the Complexity in the Management and Outcomes of Traumatic Versus Non-Traumatic Bile Leaks-A Comparative Analysis.

Digestive diseases and sciences·2025
Same author

Utility of the ESPGHAN Biopsy-Sparing Guidelines for Celiac Disease in Children.

The American journal of gastroenterology·2025
Same author

Barrett's Esophagus Epithelial Stem Cells Have Distinct Gene Signatures.

Gastro hep advances·2024
Same author

Artificial Intelligence for Real-Time Prediction of the Histology of Colorectal Polyps by General Endoscopists.

Annals of internal medicine·2024
Same author

Social determinants of health influencing the adherence to post-endoscopic mucosal resection surveillance.

Clinics and research in hepatology and gastroenterology·2024

Related Experiment Video

Updated: Dec 9, 2025

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

230

Biosimilars in inflammatory bowel disease.

Saurabh Talathi1, Kondal R Kyanam Kabir Baig2

  • 1Department of Pediatrics, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, USA.

Journal of Digestive Diseases
|September 13, 2020
PubMed
Summary

Biologics have transformed inflammatory bowel disease (IBD) treatment. Biosimilars offer a cost-effective alternative, demonstrating similar efficacy and safety profiles to biologics for IBD management.

Keywords:
Crohn diseasebiologicbiosimilar pharmaceuticalsinflammatory bowel diseasesulcerative colitis

More Related Videos

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.6K
In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

5.8K

Related Experiment Videos

Last Updated: Dec 9, 2025

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

230
Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.6K
In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

5.8K

Area of Science:

  • Gastroenterology and Immunology
  • Pharmacology and Therapeutics

Background:

  • Biologics have significantly improved outcomes in inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, over the past two decades.
  • Biologics are increasingly used as first-line therapy for severe or complicated IBD, but high healthcare costs can lead to treatment discontinuation and disease exacerbations.

Purpose of the Study:

  • To review the history and current evidence of biosimilars in the treatment of IBD.
  • To evaluate the efficacy and safety of biosimilars compared to originator biologics in IBD patients.
  • To discuss the future potential of biosimilars in managing IBD and reducing healthcare costs.

Main Methods:

  • Literature review of studies on biologics and biosimilars in IBD treatment.
  • Analysis of clinical trial data and real-world evidence on biosimilar efficacy and safety in adults and children with IBD.
  • Discussion of economic impact and future treatment paradigms.

Main Results:

  • Numerous studies in adults and children demonstrate that biosimilars are effective for IBD induction and remission.
  • Biosimilars exhibit a similar side-effect profile to their reference biologics.
  • Biosimilars present a promising strategy for reducing therapy costs in IBD management.

Conclusions:

  • Biosimilars are a viable and cost-effective therapeutic option for patients with inflammatory bowel disease.
  • The continued use and development of biosimilars are expected to enhance accessibility and sustainability of IBD treatment.
  • Further research and real-world data will continue to support the role of biosimilars in IBD care.